title: Cancer treatment in determination of hearing loss.
abstract: BACKGROUND
  Chemotherapy and radiotherapy in oncology have repercussions in hearing health, and can damage structures of the inner ear. These repercussions usually, result in a bilateral and irreversible hearing loss.
  
  
  OBJECTIVE
  To identify sensorineural hearing loss cases with complaints of tinnitus and difficulty in speech understanding and investigate their relationship with the types of chemotherapy and radiotherapy the patients received.
  
  
  METHODS
  Cross-sectional, clinical, observational, analytical, historical cohort study of 58 subjects treated in a public hospital in the state of Sergipe, diagnosed with neoplasia. The subjects were submitted to anamnesis, conventional pure tone audiometry, and speech recognition threshold.
  
  
  RESULTS
  Of the 116 ears, 25.9% presented sensorioneural hearing loss characterized by changes in high frequencies. There was a positive correlation between hearing loss and the association of chemotherapy and radiotherapy (p=0.035; R=0.196). The auditory complaint analysis shows that most of the subjects had tinnitus and speech understanding difficulty, even with a normal auditory threshold.
  
  
  CONCLUSIONS
  Cancer treatment causes hearing loss, associated with the administration of chemotherapy and radiotherapy. Cyclophosphamide increased the risk of causing hearing loss. Complaints of tinnitus and speech understanding difficulty were observed.
authors.affiliation: Doctorade in Course at Graduate Program in Health Sciences, Universidade Federal de Sergipe (UFS), São Cristóvão, SE, Brazil; Speech Pathology and Audiology Course, Universidade Federal de Sergipe (UFS), São Cristóvão, SE, Brazil. Electronic address: oliveirapriscila@hotmail.com.
authors.forename: Priscila Feliciano de
authors.initials: PF
authors.lastname: Oliveira
authors.affiliation: Speech Pathology and Audiology Course, Universidade Federal de Sergipe (UFS), São Cristóvão, SE, Brazil.
authors.forename: Camila Silva
authors.initials: CS
authors.lastname: Oliveira
authors.affiliation: Speech Pathology and Audiology Course, Universidade Federal de Sergipe (UFS), São Cristóvão, SE, Brazil.
authors.forename: Joice Santos
authors.initials: JS
authors.lastname: Andrade
authors.affiliation: Speech Pathology and Audiology Course, Universidade Federal de Sergipe (UFS), São Cristóvão, SE, Brazil.
authors.forename: Tamara Figueiredo do Carmo
authors.initials: TF
authors.lastname: Santos
authors.affiliation: Speech Pathology and Audiology Course, Universidade Federal de Sergipe (UFS), São Cristóvão, SE, Brazil; Postdoctoral Fellow in Course at Department of Speech Pathology, Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil.
authors.forename: Aline Cabral de
authors.initials: AC
authors.lastname: Oliveira-Barreto
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001301:Audiometry, Pure-Tone; D001309:Auditory Threshold; D001938:Brazil; D015331:Cohort Studies; D003430:Cross-Sectional Studies; D007758:Ear, Inner / Q000187:drug effects / Q000528:radiation effects; D005260:Female; D006319:Hearing Loss, Sensorineural / Q000209:etiology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D011878:Radiotherapy / Q000009:adverse effects*; D014012:Tinnitus / Q000139:chemically induced
chemical_list: D000970:Antineoplastic Agents
keywords: Cancer; Chemotherapy; Hearing loss; Neoplasia; Perda auditiva; Quimioterapia; Radioterapia; Radiotherapy